QMS Medical Allied Services Ltd: Valuation Shifts Signal Renewed Price Attractiveness

Valuation Metrics Signal Enhanced Price Appeal

As of 17 Feb 2026, QMS Medical’s P/E ratio stands at 19.97, a notable improvement compared to its historical averages and peer benchmarks. This figure is considerably lower than several competitors in the healthcare services sector, such as Prevest Denpro and Nureca, which trade at P/E multiples of 27.78 and 25.11 respectively. The company’s P/BV ratio of 2.04 further underscores its valuation appeal, positioning it as more reasonably priced relative to its book value than many peers.

Moreover, the enterprise value to EBITDA (EV/EBITDA) ratio of 10.59 is markedly lower than the likes of BPL and Nureca, which exhibit EV/EBITDA multiples of 64.06 and 36.80 respectively. This suggests that QMS Medical is trading at a discount on an operational earnings basis, enhancing its attractiveness for value-focused investors.

Comparative Peer Analysis Highlights Relative Value

When benchmarked against its peer group, QMS Medical’s valuation metrics stand out. While some companies such as Raaj Medisafe and Shree Pacetronix also fall into the ‘very attractive’ valuation category, QMS Medical’s combination of a moderate P/E and EV/EBITDA ratio, coupled with a PEG ratio of zero, indicates a potentially undervalued status. The PEG ratio, which factors in growth expectations, being at zero, may reflect either a lack of consensus on growth or a conservative market outlook, warranting closer scrutiny by investors.

In contrast, companies like Bandaram Pharma, despite a very attractive valuation grade, trade at an exceptionally high P/E of 143.59, which may imply overvaluation or speculative pricing. This comparative context reinforces QMS Medical’s repositioning as a more balanced and potentially rewarding investment within the healthcare services micro-cap segment.

Financial Performance and Returns: A Mixed Picture

Despite the improved valuation metrics, QMS Medical’s recent stock performance has been mixed. The company’s share price closed at ₹92.75 on 17 Feb 2026, up 5.04% on the day, with a 52-week high of ₹114.00 and a low of ₹72.35. Short-term returns have outpaced the Sensex, with a 1-month gain of 6.61% versus the Sensex’s marginal decline of 0.05%. Year-to-date, the stock has risen 3.52%, while the Sensex has fallen 1.71%.

However, longer-term returns paint a less favourable picture. Over one year, QMS Medical’s stock has declined by 8.17%, contrasting sharply with the Sensex’s 12.01% gain. The three-year return is particularly concerning, with a steep 42.12% loss compared to the Sensex’s robust 42.40% growth. This divergence highlights the challenges faced by the company in sustaining growth and investor confidence over extended periods.

Quality Metrics and Operational Efficiency

QMS Medical’s return on capital employed (ROCE) stands at 13.60%, while return on equity (ROE) is 10.20%. These figures indicate moderate operational efficiency and profitability, though they lag behind some peers in the healthcare services sector. The company’s dividend yield is modest at 0.54%, reflecting a conservative payout policy consistent with its growth and reinvestment strategy.

Enterprise value to capital employed (EV/CE) and EV to sales ratios of 1.56 and 1.64 respectively suggest that the market is valuing the company’s capital base and revenue generation at reasonable multiples, further supporting the ‘very attractive’ valuation grade assigned recently.

Mojo Score and Grade: A Cautionary Signal

Despite the positive valuation shift, QMS Medical’s overall Mojo Score remains low at 28.0, with a Mojo Grade of Strong Sell as of 4 Dec 2025, downgraded from Sell. This rating reflects underlying concerns about the company’s fundamentals, growth prospects, or market positioning that may not be fully captured by valuation metrics alone. Investors should weigh these cautionary signals against the improved price attractiveness before making investment decisions.

Contextualising Valuation in the Healthcare Services Sector

The healthcare services sector has experienced varied investor sentiment, influenced by regulatory changes, technological advancements, and evolving patient care models. Within this context, QMS Medical’s valuation improvement is noteworthy, especially given its micro-cap status and relatively modest market capitalisation grade of 4.

While some sector peers command premium valuations due to superior growth trajectories or niche market positions, QMS Medical’s repositioning as a very attractive valuation candidate may appeal to value investors seeking exposure to healthcare services without the elevated multiples seen elsewhere.

Investor Takeaway: Balancing Valuation and Fundamentals

In summary, QMS Medical Allied Services Ltd’s recent valuation parameter changes have enhanced its price attractiveness, with P/E and P/BV ratios now signalling a compelling entry point relative to peers and historical levels. However, the company’s subdued Mojo Score and mixed long-term returns counsel caution.

Investors should consider the improved valuation as one factor within a broader investment thesis, incorporating operational metrics, sector dynamics, and risk appetite. The stock’s recent outperformance against the Sensex in the short term may offer tactical opportunities, but the longer-term challenges remain a critical consideration.

Looking Ahead

Market participants will be closely monitoring QMS Medical’s upcoming quarterly results and strategic initiatives to assess whether the valuation improvement is supported by sustainable earnings growth and operational enhancements. Any positive developments could catalyse further re-rating, while setbacks may reinforce the current cautious stance.

Summary of Key Financial Metrics

• Current Price: ₹92.75 (up 5.04% on 17 Feb 2026)
• P/E Ratio: 19.97 (Very Attractive)
• Price to Book Value: 2.04
• EV/EBITDA: 10.59
• ROCE: 13.60%
• ROE: 10.20%
• Dividend Yield: 0.54%
• Mojo Score: 28.0 (Strong Sell)
• Market Cap Grade: 4

Comparative Peer Valuations

• Prevest Denpro: P/E 27.78 (Expensive), EV/EBITDA 19.58
• BPL: P/E 5.46 (Attractive), EV/EBITDA 64.06
• Raaj Medisafe: P/E 13.74 (Very Attractive), EV/EBITDA 13.89
• Shree Pacetronix: P/E 20.71 (Very Attractive), EV/EBITDA 12.09

Returns Comparison vs Sensex

• 1 Week: +1.37% vs Sensex -0.71%
• 1 Month: +6.61% vs Sensex -0.05%
• Year-to-Date: +3.52% vs Sensex -1.71%
• 1 Year: -8.17% vs Sensex +12.01%
• 3 Years: -42.12% vs Sensex +42.40%

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →